New Perspectives for SynapCell

SynapCell, a company specializing in preclinical EEG expertise for drug discovery in brain pathologies, is accelerating its growth by moving into new premises where all its activities have been brought together.

“Our gamble three years ago to target pathologies other than epilepsy, with psychiatric and movement disorders, Parkinson’s and essential tremors, has been amply validated. But we need to maintain our lead by boosting our R&D and sales“, says Corinne Roucard, the company’s president. Over the past 10 years, SynapCell has established itself as a global benchmark in the testing of anti-epileptic molecules. This expertise in studying the electrical activities of neuronal networks modified by chemical molecules enables us to assess their potential as drug candidates.

“We are now launching a major project on the early detection of neurodegenerative disorders, to identify new diagnostic markers in the early stages of a pathology“, adds Managing Director Yann Roche.

Read the full article here (in French).